JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome

[1]  J. Burke,et al.  P1062: A REAL-WORLD EVALUATION OF THE ASSOCIATION BETWEEN ELEVATED BLOOD COUNTS AND THROMBOTIC EVENTS IN POLYCYTHEMIA VERA: AN ANALYSIS OF DATA FROM THE REVEAL STUDY , 2021, Clinical lymphoma, myeloma & leukemia.

[2]  R. Silver,et al.  Normal life expectancy for polycythemia vera (PV) patients is possible , 2021, Leukemia.

[3]  U. Lehmann,et al.  Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression , 2021, European journal of haematology.

[4]  D. Campa,et al.  Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms , 2020, Blood Cancer Journal.

[5]  V. Ugo,et al.  Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study , 2020, Leukemia.

[6]  Xiaomei Ma,et al.  Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map. , 2020, Blood reviews.

[7]  M. Weirauch,et al.  SLE non-coding genetic risk variant determines the epigenetic dysfunction of an immune cell specific enhancer that controls disease-critical microRNA expression , 2020, bioRxiv.

[8]  B. Bellosillo,et al.  miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk , 2020, Leukemia.

[9]  P. Guglielmelli,et al.  Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera , 2020, British journal of haematology.

[10]  Z. Zhao,et al.  ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis , 2019, Leukemia.

[11]  A. Tefferi,et al.  The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly‐annotated patients with primary myelofibrosis , 2018, American journal of hematology.

[12]  T. Barbui,et al.  JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis , 2018, Blood Cancer Journal.

[13]  L. Anelli,et al.  The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random? , 2018, International journal of molecular sciences.

[14]  T. Barbui,et al.  Polycythemia vera treatment algorithm 2018 , 2018, Blood Cancer Journal.

[15]  P. Guglielmelli,et al.  Targeted deep sequencing in polycythemia vera and essential thrombocythemia. , 2016, Blood advances.

[16]  A. Undas,et al.  Altered plasma fibrin clot properties in essential thrombocythemia , 2015, Platelets.

[17]  M. Michalak,et al.  The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. , 2015, Thrombosis research.

[18]  E. Chen,et al.  How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms? , 2014, Hematology. American Society of Hematology. Education Program.

[19]  T. Barbui,et al.  Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. , 2014, Blood.

[20]  V. Jooste,et al.  Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients , 2013, British journal of haematology.

[21]  Bob Löwenberg,et al.  Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value , 2012, Haematologica.

[22]  L. Scott,et al.  The JAK2 exon 12 mutations: A comprehensive review , 2011, American journal of hematology.

[23]  M. Cazzola,et al.  A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications , 2010, Leukemia.

[24]  M. Cazzola,et al.  The ‘GGCC’ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera , 2009, Leukemia.

[25]  Daniel Birnbaum,et al.  Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2009, British journal of haematology.

[26]  Paola Guglielmelli,et al.  Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.

[27]  H. Hasselbalch,et al.  The JAK2 V617F mutation involves B‐ and T‐lymphocyte lineages in a subgroup of patients with Philadelphia‐chromosome negative chronic myeloproliferative disorders , 2007, British journal of haematology.

[28]  Ş. Kirazlı,et al.  The Plasma Levels of Prostanoids and Plasminogen Activator Inhibitor-1 in Primary and Secondary Thrombocytosis , 2000, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[29]  C. Gardin,et al.  Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy. , 2003, The hematology journal : the official journal of the European Haematology Association.